Pharmaceutical applications of mucoadhesion for the non-oral routes

被引:120
作者
Edsman, K [1 ]
Hägerström, H [1 ]
机构
[1] Uppsala Univ, Uppsala Biomed Ctr, Dept Pharm, SE-75123 Uppsala, Sweden
关键词
D O I
10.1211/0022357055227
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The adhesion of pharmaceutical formulations to the mucosal tissue offers the possibility of creating an intimate and prolonged contact at the site of administration. This prolonged residence time car. result in enhanced absorption and, in combination with a controlled release of the drug, also improved patient compliance by reducing the frequency of administration. During the almost. 30 years over which mucoadhesion has been studied, a considerable amount of knowledge has been gained, and much has been learned about the different mechanisms occurring at the formulation-mucus interface and the properties that affect these mechanisms. The in-vivo, performance of a dosage form not only depends on the mechanisms occurring at the interface, but also on the properties of the total mucoadhesive complex: the dosage form, the mucosa and the interface between them. A wide variety of methods are used for studying mucoadhesion; some rather similar to the in-vivo situation and some mimicking the interface alone. In this review, the mucus surface, the methods used for the study of mucoadhesion, the different mechanisms involved in mucoadhesion and theories underpinning them have been described. The complexity of mucoadhesion when trying to systemize the subject will also be discussed. The last part of the review describes the buccal, nasal, ocular, vaginal and rectal routes and provides examples of what can be achieved in-vivo when using mucoadhesive formulations.
引用
收藏
页码:3 / 22
页数:20
相关论文
共 192 条
  • [21] Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability
    Callens, C
    Pringels, E
    Remon, JP
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 250 (02) : 415 - 422
  • [22] Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol® 974 P on rabbit nasal mucosa and slug mucosa
    Callens, C
    Adriaens, E
    Dierckens, K
    Remon, JP
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 76 (1-2) : 81 - 91
  • [23] Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
    Calvo, P
    VilaJato, JL
    Alonso, MJ
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (01) : 41 - 50
  • [24] Campbell BJ, 1999, DRUGS PHARM SCI, V98, P85
  • [25] CARAMELLA C, 1994, EUR J PHARM BIOPHARM, V40, P213
  • [26] CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40
  • [27] Ceulemans J, 2002, PHARMAZIE, V57, P181
  • [28] Chang JY, 2002, J CONTROL RELEASE, V82, P39, DOI 10.1016/S0168-3659(02)00086-X
  • [29] Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms
    Chatterton, BE
    Penglis, S
    Kovacs, JC
    Presnell, B
    Hunt, B
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) : 137 - 143
  • [30] Chen J.L., 1970, ADHESION BIOL SYSTEM, P163, DOI 10.1016/b978-0-12-469050-9.50015-6